New England Journal of Medicine· 2017Q1· Review
Acute Graft-versus-Host Disease — Biologic Process, Prevention, and Therapy
- 1,295citations
- Q1SCImago
- 2017year
Short summary
Acute graft-versus-host disease (aGVHD) occurs when donor T cells attack host tissues within 3 months post-hematopoietic-cell transplantation, primarily affecting skin, liver, and the gastrointestinal tract.
AI-generated from the title and abstract; the full text is not read.
Key points
- Acute graft-versus-host disease (aGVHD) is triggered by donor T cells attacking host tissues.
- The onset of aGVHD typically occurs within 3 months after hematopoietic-cell transplantation.
- Primary target organs for aGVHD include the skin, liver, and gastrointestinal tract.
- Current treatment for aGVHD involves the use of immunosuppressive drugs.
AI-generated from the title and abstract; the full text is not read.
Abstract
When T cells from a bone marrow donor begin to attack the host within 3 months after hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease mainly affects the skin, liver, and gastrointestinal tract and is treated with immunosuppressive drugs.
The authors' abstract, as published at the source. New England Journal of Medicine, 2017 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Hematology
HematologyMedicine